NYSE:NVO - Novo Nordisk A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$49.66 -0.04 (-0.08 %)
(As of 02/22/2019 07:04 AM ET)
Previous Close$49.70
Today's Range$49.40 - $49.82
52-Week Range$41.23 - $54.56
Volume757,936 shs
Average Volume1.41 million shs
Market Capitalization$121.35 billion
P/E Ratio19.71
Dividend Yield1.32%
Beta0.68
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.72 billion
Cash Flow$2.7482 per share
Book Value$3.24 per share

Profitability

Net Income$5.91 billion

Miscellaneous

Employees43,202
Outstanding Shares2,443,530,000
Market Cap$121.35 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a special dividend on Thursday, August 9th. Stockholders of record on Monday, August 20th will be given a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date is Friday, August 17th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its board has initiated a share repurchase program on Friday, February 2nd 2018, which authorizes the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Friday, February, 1st. The company reported $0.54 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.57 by $0.03. The firm earned $4.55 billion during the quarter, compared to the consensus estimate of $4.36 billion. Novo Nordisk A/S had a return on equity of 80.45% and a net margin of 34.67%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Novo Nordisk A/S.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2019 earnings guidance on Friday, February, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.446-17.949 billion, compared to the consensus revenue estimate of $17.91 billion.

What price target have analysts set for NVO?

15 brokerages have issued 12 month price targets for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $48.61. On average, they expect Novo Nordisk A/S's stock price to reach $48.61 in the next year. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

News headlines about NVO stock have trended somewhat positive on Friday, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), Pfizer (PFE), Celgene (CELG), Johnson & Johnson (JNJ), Cisco Systems (CSCO), General Electric (GE), AbbVie (ABBV), Intel (INTC), Alibaba Group (BABA) and QUALCOMM (QCOM).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Jesper Brandgaard, Exec. VP of Biopharm, Global Legal & Patents (Age 56)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 53)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.58%), Bank of America Corp DE (0.48%), BlackRock Inc. (0.35%), Folketrygdfondet (0.23%), Sustainable Growth Advisers LP (0.15%) and Northern Trust Corp (0.09%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, BlackRock Inc., First Trust Advisors LP, PNC Financial Services Group Inc., Connor Clark & Lunn Investment Management Ltd., Sustainable Growth Advisers LP, Stifel Financial Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Boston Partners, Fisher Asset Management LLC, Avalon Advisors LLC, Two Sigma Advisers LP, CIBC Asset Management Inc, NorthCoast Asset Management LLC, Northern Trust Corp and Canada Pension Plan Investment Board. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $49.66.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $121.35 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  371 (Vote Underperform)
Total Votes:  656
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel